Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER STUDY OF SAGE-718 USING A KETAMINE CHALLENGE, TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMIC RESPONSE USING MAGNETIC RESONANCE IMAGING IN HEALTHY SUBJECTS


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT03770780

Organisation Name: Sage Therapeutics

Overal Status: Completed

Start Date: November 12, 2018

Last Update: May 1, 2019

Lead Sponsor: Sage Therapeutics

Brief Summary: This study is a phase 1, double-blind, placebo-controlled crossover study of SAGE-718 using a ketamine challenge, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic response using magnetic resonance imaging in healthy subjects

Conditions:
  • Healthy Volunteer


Total execution time in seconds: 0.1456880569458